In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approval request, ICER and Verdant Research publish a new white paper examining the evolution and future of the FDA's accelerated approval pathway, and a new Pharmaceutical Executive commentary argues FDA's shift toward single-trial approval standards marks the beginning of a genuinely new era in data-driven drug development.
Fler avsnitt av Pharmaceutical Executive
Visa alla avsnitt av Pharmaceutical ExecutivePharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
